Using blood markers to help diagnose and predict colorectal cancer
Neutrophil-to-Lymphocite Ratio (NLR) and C-reactive Protein (CRP) as New Markers in Diagnosis and Prediction of Surgical and Oncological Outcomes in Colorectal Cancer
This study is testing if certain blood markers can help doctors better diagnose colorectal cancer and predict how well patients will do after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria Academic / other |
| Locations | 2 sites (Alessandria and 1 other locations) |
| Trial ID | NCT05129046 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive Protein (CRP) as potential biomarkers for diagnosing and predicting outcomes in colorectal cancer patients. By analyzing these blood markers, the study seeks to identify high-risk patients and improve follow-up care and treatment decisions post-surgery. The research is motivated by the need for better screening methods and the poor overall survival rates associated with colorectal cancer. The study will involve patients who are eligible for minimally invasive or open surgical procedures for colorectal cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with histologically-proven adenocarcinoma of the colon or rectum who are eligible for surgical intervention.
Not a fit: Patients with squamous carcinoma of the anal canal or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and better management of colorectal cancer, ultimately enhancing patient survival rates.
How similar studies have performed: While the use of NLR and CRP as biomarkers is being explored, this specific approach in colorectal cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years * Histologically-proven adenocarcinoma of the colon or the rectum * Eligible for a resective surgery by minimally-invasive (standard or robotic-assisted laparoscopic procedure, all robotic systems will be accepted) or open approach * Able to give written informed consent Exclusion Criteria: * Squamous carcinoma of the anal canal * History of psychiatric or addictive disorder or other medical condition that, in the opinion of the investigator, would preclude the patient from meeting the trial requirements * Pregnancy * Unable to give free informed consent
Where this trial is running
Alessandria and 1 other locations
- SS. Antonio e Biagio e Cesare Arrigo — Alessandria, Italy (Recruiting)
- San Raffaele Hospital — Milan, Italy (Enrolling_by_invitation)
Study contacts
- Study coordinator: Igor Monsellato, PhD
- Email: igor.monsellato@ospedale.al.it
- Phone: +390131206078
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.